CSF1R and neoplasm: As anti-CSF-1R only enhanced the efficacy of combined IT against TC-1/A9 tumors, we next investigated whether a similar tumor growth inhibition could be achieved in this tumor type, using the same dose number of either ODN1826 or anti-CSF-1R, applied separately into the immunized mice.